Knoll Capital Management, LLC
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), Knoll Capital Management, LLC reported 37 stock positions worth $188.7 million. Its top holding was Biohaven Pharmaceutical Hold at 10.4% of the portfolio, followed by Sprott Physical Gold Trust (PHYS, 7.3%) and Royal Gold (RGLD, 7.1%). Compared with Q4 2025, it opened 8 new positions, sold out of 4, added to 3 and reduced 3. The biggest buy was a new position in Sprott Physical Gold Trust (PHYS) and the biggest sale an exit from Avadel Pharmaceuticals plc (AVDL).
- Most Recent 13F
- Q2 2026
- Location
- MIAMI, FL
- CIK
- 0001325083
- Portfolio Value
- $188.7M (Q1 2026)
- SEC Filing
- 0001104659-26-062445 ↗ filed May 15, 2026
Holdings Value
Holdings 37 stocks · $188.7M
| BIOHAVEN PHARMACEUTICAL HOLD | 10.44% | 2,328,602 | $19.7M | No change |
| PHYS Sprott Physical Gold Trust | 7.27% | 387,055 | $13.7M | New |
| RGLD Royal Gold Inc. | 7.11% | 52,750 | $13.4M | No change |
| MGTX Meiragtx Holdings PLC | 5.74% | 1,250,000 | $10.8M | No change |
| AEM Agnico Eagle Mines Ltd. | 5.67% | 52,750 | $10.7M | No change |
| KGC Kinross Gold Corp. | 5.18% | 320,000 | $9.8M | Reduce -21.9% |
| ALDX Aldeyra Therapeutics Inc. | 4.90% | 5,475,516 | $9.3M | No change |
| SA Seabridge Gold Inc. | 4.76% | 317,003 | $9.0M | No change |
| OR Or Royalties Inc. | 4.53% | 225,000 | $8.6M | New |
| FNV Franco-Nevada Corp. | 4.19% | 32,000 | $7.9M | Add +28.0% |
| SSRM SSR Mining Inc. | 3.82% | 245,000 | $7.2M | No change |
| ELTX Elicio Therapeutics Inc. | 3.57% | 630,915 | $6.7M | No change |
| ENTX Entera Bio Ltd. | 3.43% | 5,881,879 | $6.5M | No change |
| NUVB Nuvation Bio Inc. | 3.41% | 1,498,591 | $6.4M | No change |
| CGAU Centerra Gold Inc. | 3.38% | 359,000 | $6.4M | Reduce -27.8% |
| PAAS Pan American Silver Corp. | 2.90% | 100,035 | $5.5M | No change |
| PSLV Sprott Physical Silver Trust | 2.87% | 222,160 | $5.4M | New |
| OCUL Ocular Therapeutix Inc. | 2.69% | 600,400 | $5.1M | No change |
| TFPM Triple Flag Precious Met | 2.12% | 115,000 | $4.0M | Add +95.6% |
| GROY Gold Royalty Corp. | 1.90% | 1,000,000 | $3.6M | New |
| AGI Alamos Gold Inc. Class A | 1.18% | 50,000 | $2.2M | No change |
| ABEO Abeona Therapeutics Inc. | 1.15% | 485,515 | $2.2M | Add +105.8% |
| NEWP New Pacific Metals Corp. | 1.06% | 485,000 | $2.0M | No change |
| CDE Coeur Mining Inc. | 0.96% | 96,132 | $1.8M | No change |
| ITA iShares U.S. Aerospace & Def | 0.89% | 7,650 | $1.7M | No change |
| PM Philip Morris International | 0.88% | 10,000 | $1.7M | No change |
| WPM Wheaton Precious Metals Corp. | 0.87% | 12,500 | $1.6M | No change |
| NOC Northrop Grumman Corp. | 0.78% | 2,165 | $1.5M | No change |
| BAH Booz Allen Hamilton Holdings | 0.54% | 13,000 | $1.0M | No change |
| ELE Elemental Royalty Corp. | 0.50% | 50,000 | $943K | New |
| VMET Versamet Royalties Corp. | 0.34% | 66,621 | $634K | New |
| DC Dakota Gold Corp. | 0.33% | 122,921 | $621K | No change |
| AMRZ Amrize Ltd. | 0.27% | 9,175 | $514K | New |
| ALT Altimmune Inc. | 0.26% | 160,000 | $493K | Reduce -85.7% |
| CRDL Cardiol Therapeutics Inc. Class A | 0.07% | 100,000 | $135K | No change |
| PHAR Pharming Group NV - ADR | 0.04% | 4,057 | $68K | New |
| Orgenesis, Inc. | 0.02% | 50,623 | $30K | No change |
Portfolio Sells Q4 2025 → Q1 2026
| AVDL Avadel Pharmaceuticals plc | Sold out | 0.00% | −5.93 |
| GLD SPDR Gold Shares | Sold out | 0.00% | −5.82 |
| SLV iShares Silver Trust | Sold out | 0.00% | −2.36 |
| ALT Altimmune Inc. | Reduce -85.7% | 0.26% | −1.60 |
| APLT Applied Therapeutics Inc. | Sold out | 0.00% | −0.28 |
| KGC Kinross Gold Corp. | Reduce -21.9% | 5.18% | −0.12 |
| CGAU Centerra Gold Inc. | Reduce -27.8% | 3.38% | +0.11 |
Portfolio Buys Q4 2025 → Q1 2026
| PHYS Sprott Physical Gold Trust | New | 7.27% | +7.27 |
| OR Or Royalties Inc. | New | 4.53% | +4.53 |
| PSLV Sprott Physical Silver Trust | New | 2.87% | +2.87 |
| GROY Gold Royalty Corp. | New | 1.90% | +1.90 |
| FNV Franco-Nevada Corp. | Add +28.0% | 4.19% | +1.81 |
| TFPM Triple Flag Precious Met | Add +95.6% | 2.12% | +1.22 |
| ABEO Abeona Therapeutics Inc. | Add +105.8% | 1.15% | +0.58 |
| ELE Elemental Royalty Corp. | New | 0.50% | +0.50 |
| VMET Versamet Royalties Corp. | New | 0.34% | +0.34 |
| AMRZ Amrize Ltd. | New | 0.27% | +0.27 |
| PHAR Pharming Group NV - ADR | New | 0.04% | +0.04 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026Amended | 37 | $214.3M | BIOHAVEN PHARMACEUTICAL HOLD, MGTX, PHYS, ALDX, OCUL |
| Q1 2026 | 37 | $188.7M | BIOHAVEN PHARMACEUTICAL HOLD, PHYS, RGLD, MGTX, AEM |
| Q4 2025 | 33 | $218.0M | ALDX, BIOHAVEN PHARMACEUTICAL HOLD, NUVB, AVDL, GLD |
| Q3 2025 | 38 | $186.6M | ALDX, BIOHAVEN PHARMACEUTICAL HOLD, GLD, ENTX, MGTX |
| Q2 2025 | 38 | $140.7M | ALDX, BIOHAVEN PHARMACEUTICAL HOLD, ENTX, GLD, MGTX |
| Q1 2025 | 36 | $153.7M | ALDX, BIOHAVEN PHARMACEUTICAL HOLD, ENTX, GLD, MGTX |
| Q4 2024 | 35 | $155.3M | BIOHAVEN PHARMACEUTICAL HOLD, ALDX, ENTX, VRNA, ALT |
| Q3 2024 | 36 | $215.8M | APLT, BIOHAVEN PHARMACEUTICAL HOLD, ALDX, AGI, AVDL |
| Q2 2024 | 35 | $148.4M | APLT, BIOHAVEN PHARMACEUTICAL HOLD, ALDX, AVDL, ALT |
| Q1 2024 | 34 | $160.7M | APLT, BIOHAVEN PHARMACEUTICAL HOLD, ALDX, AVDL, GLD |